drug evaluation

Summary

Summary: Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.

Top Publications

  1. ncbi Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
    Daniel Truong
    The Parkinson s and Movement Disorders Institute, Fountain Valley, California 92708, USA
    Mov Disord 20:783-91. 2005
  2. pmc Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation
    Maria Vinci
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK
    BMC Biol 10:29. 2012
  3. ncbi Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
    Bodil Als-Nielsen
    The Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark
    JAMA 290:921-8. 2003
  4. ncbi Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications
    Beate Wieseler
    Institute for Quality and Efficiency in Health Care, Dillenburger Strasse 27, 51105 Cologne, Germany
    BMJ 344:d8141. 2012
  5. ncbi Applications of accelerator MS in pediatric drug evaluation
    L T Vuong
    Vitalea Science, Inc, Davis, CA 95618, USA
    Bioanalysis 4:1871-82. 2012
  6. ncbi Geriatric drug evaluation: where are we now and where should we be in the future?
    Seongeun Cho
    Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
    Arch Intern Med 171:937-40. 2011
  7. ncbi NK-cell activity in immunotoxicity drug evaluation
    Karin Cederbrant
    Department of Molecular Toxicology Immunotoxicology, Safety Assessment, AstraZeneca R and D Sodertalje, SE 151 85, Sodertalje, Sweden
    Toxicology 185:241-50. 2003
  8. ncbi An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update)
    Athena Philis-Tsimikas
    Scripps Whittier Diabetes Institute, 9894 Genesee Avenue, Suite 316, La Jolla, CA 92037, USA
    Expert Opin Pharmacother 9:2181-95. 2008
  9. ncbi Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency
    Andreas Billich
    Novartis Institutes for BioMedical Research, Brunner Strasse 59, A 1235 Wien, Austria
    IDrugs 10:53-9. 2007
  10. ncbi Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program
    Pellegrino Musto
    Unit of Hematology and Stem Cell Transplantation, IRCCS, Centro di Riferimento Oncologico della Basilicata, via Padre Pio 1, 85028 Rionero in Vulture, Potenza, Italy
    Cancer 116:1485-94. 2010

Detail Information

Publications250 found, 100 shown here

  1. ncbi Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
    Daniel Truong
    The Parkinson s and Movement Disorders Institute, Fountain Valley, California 92708, USA
    Mov Disord 20:783-91. 2005
    ..These results confirm previous reports that Dysport (500 units) is safe, effective, and well-tolerated in patients with cervical dystonia...
  2. pmc Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation
    Maria Vinci
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK
    BMC Biol 10:29. 2012
    ..However, most currently available three-dimensional techniques are time consuming and/or lack reproducibility; thus standardized and rapid protocols are urgently needed...
  3. ncbi Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
    Bodil Als-Nielsen
    The Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark
    JAMA 290:921-8. 2003
    ..Previous studies indicate that industry-sponsored trials tend to draw proindustry conclusions...
  4. ncbi Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications
    Beate Wieseler
    Institute for Quality and Efficiency in Health Care, Dillenburger Strasse 27, 51105 Cologne, Germany
    BMJ 344:d8141. 2012
    ..To investigate to what extent three types of documents for reporting clinical trials provide sufficient information for trial evaluation...
  5. ncbi Applications of accelerator MS in pediatric drug evaluation
    L T Vuong
    Vitalea Science, Inc, Davis, CA 95618, USA
    Bioanalysis 4:1871-82. 2012
    ..The technology is by no means a panacea for the deficiency in pediatric clinical research; however, it lessens the challenges and provides the most quantitative tool for pediatric pharmacology studies...
  6. ncbi Geriatric drug evaluation: where are we now and where should we be in the future?
    Seongeun Cho
    Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
    Arch Intern Med 171:937-40. 2011
    ....
  7. ncbi NK-cell activity in immunotoxicity drug evaluation
    Karin Cederbrant
    Department of Molecular Toxicology Immunotoxicology, Safety Assessment, AstraZeneca R and D Sodertalje, SE 151 85, Sodertalje, Sweden
    Toxicology 185:241-50. 2003
    ..However, a new flow-cytometric assay, adapted for rat peripheral blood, does not require dedicated groups of animals, offers the possibility of repeated testing, and shows at least as sensitive as the conventional 51Cr-release assay...
  8. ncbi An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update)
    Athena Philis-Tsimikas
    Scripps Whittier Diabetes Institute, 9894 Genesee Avenue, Suite 316, La Jolla, CA 92037, USA
    Expert Opin Pharmacother 9:2181-95. 2008
    ..This article reviews new evidence, in particular on the weight-sparing effect of detemir and its use in type 2 diabetes...
  9. ncbi Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency
    Andreas Billich
    Novartis Institutes for BioMedical Research, Brunner Strasse 59, A 1235 Wien, Austria
    IDrugs 10:53-9. 2007
    ..From the data available to date, apilimod appears to be a promising treatment for CD, and the oral formulation of this compound provides an advantage for apilimod over injectable therapies...
  10. ncbi Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program
    Pellegrino Musto
    Unit of Hematology and Stem Cell Transplantation, IRCCS, Centro di Riferimento Oncologico della Basilicata, via Padre Pio 1, 85028 Rionero in Vulture, Potenza, Italy
    Cancer 116:1485-94. 2010
    ..However, limited data are available concerning the efficacy and safety of azacitidine in patients who have lower risk MDS...
  11. pmc Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
    Hans Melander
    Medical Products Agency, Box 23, S 751 03 Uppsala, Sweden
    BMJ 326:1171-3. 2003
    ..To investigate the relative impact on publication bias caused by multiple publication, selective publication, and selective reporting in studies sponsored by pharmaceutical companies...
  12. ncbi Keeping science on top in drug evaluation
    Jerry Avorn
    Harvard Medical School and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women s Hospital, Boston, USA
    N Engl J Med 357:633-5. 2007
  13. ncbi Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome
    Changhai Ding
    Menzies Research Institute, University of Tasmania, Hobart, Tasmania 7000, Australia
    Curr Opin Investig Drugs 7:1020-5. 2006
    ..In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006...
  14. ncbi Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas
    J P Ioannidis
    Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
    JAMA 285:437-43. 2001
    ..Current standards for safety reporting in randomized trials should be revised to address this inadequacy...
  15. pmc Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study
    Christopher V Plowe
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1 480, Baltimore, MD 21044, USA
    BMJ 328:545. 2004
    ..To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line treatment in that country in 1993...
  16. ncbi Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study
    Eli O Meltzer
    Allergy and Asthma Medical Group and Research Center, San Diego, California, USA
    Ann Allergy Asthma Immunol 90:79-86. 2003
    ..Patients with allergic rhinitis have a wide range of symptoms that are often treated with oral combination products that contain antihistamines, decongestants, and analgesics...
  17. ncbi Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study
    Enrique Alvarez
    Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
    Eur Neuropsychopharmacol 13:39-48. 2003
    ..This study was designed to assess the safety and effectiveness of olanzapine compared to typical antipsychotics drugs in the treatment of schizophrenic inpatients at acute psychiatric in-patient units...
  18. ncbi [Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination]
    F Fouyssac
    Service d hémato oncologie pédiatrique, hôpital d enfants, CHU de Nancy, 54500 Vandoeuvre Lès Nancy, France
    Med Mal Infect 35:357-62. 2005
    ..The authors had for aim to assess the effectiveness and toxicity of a piperacillin-tazobactam-netilmicin combination, and the possibility of avoiding using glycopeptide, in children with febrile neutropenic episodes induced by chemotherapy...
  19. ncbi Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus
    Martin I Freed
    GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
    Am J Cardiol 90:947-52. 2002
    ....
  20. ncbi A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect
    Matthew Brams
    Baylor College of Medicine, Houston, Texas 77019, USA
    CNS Drugs 22:693-704. 2008
    ..5 hours post-dose on the Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP) rating scale...
  21. ncbi The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial
    Par Hallberg
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    J Hypertens 20:2089-93. 2002
    ..However, its influence on clinical response to treatment with the AT(1) receptor antagonist, irbesartan, has not been investigated...
  22. ncbi A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy
    Mark E Sale
    Pharmacokinetic Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC, USA
    Epilepsy Behav 6:63-70. 2005
    ....
  23. ncbi Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients
    L Josselin
    Department of Internal Medicine, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Rheum Dis 67:1343-6. 2008
    ..However, its safety and ability to induce and maintain remission over the long term remain unknown...
  24. ncbi Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension
    Kenneth A Jamerson
    Division of Hypertension, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 481009, USA
    Am J Hypertens 17:495-501. 2004
    ....
  25. ncbi Escalating immunotherapy of multiple sclerosis--new aspects and practical application
    P Rieckmann
    Dept of Neurology, Josef Schneider Str 11, 97080, Wurzburg, Germany
    J Neurol 251:1329-39. 2004
    ..Moreover, in long-term treated patients, secondary treatment failure should be identified by pre-planned follow-up examinations, and other treatment options should then be considered...
  26. ncbi Efficacy and safety of Losigamone in partial seizures: a randomized double-blind study
    M Baulac
    Epilepsy Unit, INSERM 0224, CHU Pitie Salpetriere, 91, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Epilepsy Res 55:177-89. 2003
    ..Over the last 4 weeks of treatment, the incidence of adverse events in the LSG groups was close to the placebo level. Based on the study's results, LSG is an effective and safe add-on drug for refractory partial epilepsy in adults...
  27. ncbi Tolcapone: a review of its use in the management of Parkinson's disease
    Gillian M Keating
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    CNS Drugs 19:165-84. 2005
    ..Thus, tolcapone is a useful option in patients with fluctuating Parkinson's disease who are receiving levodopa/DDCI and are not responding to, or are not candidates for, other adjunctive treatments...
  28. ncbi Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease
    William G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 20:958-63. 2005
    ..Larger doses of drug and greater sample sizes might be considered in future studies...
  29. ncbi Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial
    H J Moller
    Department of Psychiatry, Ludwig Maximilians University, Nussbaumstrasse 7, 80336 Munich, Germany
    Pharmacopsychiatry 37:270-8. 2004
    ..Zotepine, a D (2)5HT (2A) antagonist, was compared to placebo in this clinical trial to address these issues...
  30. ncbi Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS
    Gordon S Francis
    J Neurol 251:v42-v49. 2004
    ....
  31. ncbi Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy
    S Grosso
    Pediatrics Department, University of Siena, Ospedale Santa Maria alle Scotte, Via M Bracci, 53100 Siena, Italy
    Seizure 14:248-53. 2005
    ..Our preliminary data also indicate that levetiracetam may be a valid therapeutic option for epilepsy in infants and young children...
  32. ncbi The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease
    Sarah Thompson
    Sunnybrook and Women s College Health Sciences Centre, Department of Psychiatry, Rm FG 05, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
    Expert Opin Drug Saf 3:425-40. 2004
    ..Further study is needed to examine other indications for ChEIs, as well as their combination with newer treatments, such as memantine...
  33. ncbi An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy
    B Abou-Khalil
    Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    Seizure 12:141-9. 2003
    ..The primary aim of this study was to measure the safety and tolerability of LEV individualised dosing in a heterogeneous refractory epilepsy population...
  34. ncbi Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study
    Tim Betts
    Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham, B15 2QZ, UK
    Seizure 12:136-40. 2003
    ..Our audit of its use and effectiveness has led us to position it as our first choice add-on drug if the initial monotherapy drug fails...
  35. pmc Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial
    A D Beaulieu
    Centre de Rhumatologie St Louis, Ste Foy, Canada
    Pain Res Manag 13:103-10. 2008
    ..The present study was a randomized, parallel, double-blind comparison between controlled-release (CR) tramadol and sustained-release (SR) diclofenac in patients with chronic pain due to osteoarthritis of the hips and/or knees...
  36. ncbi Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine
    Andrew M Blumenfeld
    The Neurology Center, Encinitas, CA 92024, USA
    Headache 48:210-20. 2008
    ..To compare the efficacy and safety of botulinum toxin type A (BoNTA; BOTOX: Allergan, Inc.) and divalproex sodium (DVPX; DEPAKOTE: Abbott Laboratories) as prophylaxis in reducing disability and impact associated with migraine...
  37. ncbi Initial experience with routine administration of etanercept in psoriasis
    M de Groot
    Department of Dermatology A0 252, Academic Medical Centre, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Br J Dermatol 155:808-14. 2006
    ....
  38. ncbi The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
    Martin B Keller
    Brown University, Providence, Rhode Island 02906, USA
    Biol Psychiatry 62:1371-9. 2007
    ..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment...
  39. ncbi Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke
    K R Lees
    University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK
    Stroke 32:675-80. 2001
    ..Population pharmacokinetic analysis estimated clearance to be 4.6 L/h. CONCLUSIONS: NXY-059 was well tolerated in patients with an acute stroke. The testing of higher doses in future trials may be justified...
  40. ncbi Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
    L Kappos
    University of Basel, Basel, Switzerland
    Neurology 67:944-53. 2006
    ..c.) interferon (IFN) beta-1a in relapsing-remitting multiple sclerosis (RRMS)...
  41. ncbi A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy
    Crit Rev Oncol Hematol 61:84-9. 2007
    ..The higher therapeutic index of Caelyx 50 mg/m(2) every 4 weeks makes it, of the two dose schedules investigated, the preferred regimen in the elderly...
  42. ncbi [Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis]
    Marc Miravitlles
    Servei de Pneumologia, Institut Clínic del Tòrax IDIBAPS, Hospital Clinic, Barcelona, Espana
    Arch Bronconeumol 43:22-8. 2007
    ..Our objective was to compare the clinical efficacy of moxifloxacin to that of the antibiotic regimens routinely used to treat such exacerbations by a systematic review of the literature and a meta-analysis...
  43. ncbi Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
    C Kalpadakis
    First Department of Internal Medicine, National Kapodistrian University of Athens, Laikon University Hospital, Athens, Greece
    Hematol Oncol 25:127-31. 2007
    ..No deaths were recorded during the follow-up period. Therapy was well tolerated. The present study demonstrates that rituximab is an effective treatment for SMZL and could be considered as a substitute or alternative to splenectomy...
  44. ncbi [A descriptive study of erythropoietin use and cost in hematologic patients]
    A Pelufo Pellicer
    Servicio de Farmacia, Hospital Universitario La Fe, Valencia, Spain
    Farm Hosp 30:343-50. 2006
    ....
  45. ncbi Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies
    Felicia Cosman
    Helen Hayes Hospital, West Haverstraw, New York 10993, USA
    Clin Ther 29:1116-27. 2007
    ..Although a number of trial designs can be used to consider the efficacy of therapy, comparing the efficacy of different regimens should only be undertaken in purposefully designed head-to-head studies...
  46. ncbi Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study
    Giangennaro Coppola
    Clinic of Child Neuropsychiatry, Department of Pediatrics, Second University of Naples, Via Pansini, 5, 80131, Naples, Italy
    Epilepsy Res 51:147-53. 2002
    ..In conclusion, TPM adjunctive therapy reduced the number of drop attacks and major motor seizures in 40% of patients with LGS and produced only mild or moderate adverse events...
  47. ncbi Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine
    Christer Allgulander
    Karolinska Institutet, The Neurotec Department, Section of Psychiatry, Stockholm, Sweden
    Hum Psychopharmacol 19:387-96. 2004
    ..Both active treatments were generally well tolerated and were associated with a similar incidence of adverse events. This study shows that venlafaxine ER is an effective, safe and well-tolerated drug treatment for SAD...
  48. ncbi Association between pharmaceutical involvement and outcomes in breast cancer clinical trials
    Jeffrey Peppercorn
    Division of Hematology Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Cancer 109:1239-46. 2007
    ..In this study, the authors sought to evaluate the impact of this shift in funding from public to private sponsors on the nature of published breast cancer clinical research...
  49. ncbi Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months
    J E Piña-Garza
    Vanderbilt University, Children s Hospital at Vanderbilt, Nashville, TN 37232 9559, USA
    Neurology 70:2099-108. 2008
    ..This randomized, double-blind, placebo-controlled trial was conducted to assess the efficacy and tolerability of adjunctive lamotrigine for the treatment of partial seizures in infants aged 1 to 24 months...
  50. ncbi [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo]
    A Elira Dokekias
    Service hématologie, CHU Brazzaville, BP 13027 RP, Brazzaville, Congo
    Bull Soc Pathol Exot 101:109-12. 2008
    ....
  51. ncbi A retrospective postlicensure survey of FEIBA efficacy and safety
    D Dimichele
    New York Presbyterian Weill Cornell Center, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
    Haemophilia 12:352-62. 2006
    ..Results indicated that FEIBA was safe and effective in acute, surgical, and prophylactic treatment settings, supporting the utility of FEIBA as a treatment option for patients with inhibitors. However, prospective studies are advised...
  52. ncbi Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes
    S James
    Department of Cardiology, Thoraxcenter, Academic Hospital, Uppsala, Sweden
    Eur Heart J 23:1538-45. 2002
    ..The safety and efficacy of abciximab in addition to low-molecular-weight-heparin as the primary medical treatment of acute coronary syndromes has not previously been investigated...
  53. ncbi Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure
    Dong H Shin
    Kresge Eye Institute, Wayne State University, Detroit, Michigan, USA
    Ophthalmology 111:276-82. 2004
    ..To compare the efficacy and safety of the fixed combination of latanoprost and timolol with those of the fixed combination of dorzolamide and timolol in patients with elevated intraocular pressure (IOP)...
  54. ncbi Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention
    Young Joon Hong
    The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea
    Circ J 70:1269-74. 2006
    ..This study assessed the effects of combination therapy with simvastatin and carvedilol on clinical outcome in patients with left ventricular (LV) dysfunction after acute myocardial infarction (AMI)...
  55. ncbi Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections
    C Sanz-Rodriguez
    Department of Clinical Research, Merck Sharp and Dohme of Spain, Madrid, Spain
    Bone Marrow Transplant 34:13-20. 2004
    ..In this study of a limited number of patients, the coadministration of caspofungin and CsA was generally well tolerated...
  56. ncbi Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases
    Carlos Conill
    Department of Radiation Oncology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Clin Transl Oncol 8:266-70. 2006
    ..The objective was to evaluate the potential benefit in survival of two different schedules of total dose and fractionation (20 Gy/5 fractions vs 30 Gy/10 fractions) and further TMZ based chemotherapy...
  57. ncbi Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial
    Eve J Higginbotham
    Department of Ophthalmology, University of Maryland School of Medicine, 419 W Redwood St, Suite 580, Baltimore, MD 21201, USA
    Arch Ophthalmol 120:915-22. 2002
    ..To compare the efficacy and safety of a fixed combination of 0.005% latanoprost and 0.5% timolol maleate administered once daily vs monotherapy with either 0.005% latanoprost once daily or 0.5% timolol twice daily...
  58. ncbi Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease
    L Giaccone
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Bone Marrow Transplant 36:337-41. 2005
    ..From this preliminary analysis, MTX appears to be a well-tolerated, inexpensive and possibly steroid-sparing agent that is worthy of further evaluation in prospective trials for treatment of chronic GVHD...
  59. ncbi Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day
    Robert S Rosenson
    Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Am J Cardiol 91:878-81. 2003
  60. ncbi Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease
    D Lillicrap
    Department of Pathology, Queen s University, Kingston, Ontario, Canada
    Thromb Haemost 87:224-30. 2002
    ..The findings in this study confirm the safety and efficacy of Haemate-P/Humate-P using VWF:RCo dosing in pediatric and adult patients with various types of VWD...
  61. ncbi Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension
    William B White
    Section of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, 263 Farmngton Avenue, Farmington, CT 06032, USA
    Am J Hypertens 16:739-45. 2003
    ....
  62. ncbi One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
    Claudia Trenkwalder
    Max Planck Institute of Psychiatry, Munich, Germany
    Mov Disord 18:1184-9. 2003
    ....
  63. ncbi Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial
    Stephen M Davis
    Department of Neurology, Royal Melbourne Hospital, University of Melbourne, Australia
    Lancet Neurol 7:299-309. 2008
    ..We aimed to test whether alteplase given 3-6 h after stroke onset promotes reperfusion and attenuates infarct growth in patients who have a mismatch in perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI)...
  64. ncbi Lamotrigine therapy in patients requiring a change in antiepileptic drug regimen
    Robert P Kustra
    Epilepsy Clinical Development, GlaxoSmithKline, P O Box 13398, Research Triangle Park, NC 27709, USA
    Seizure 14:254-61. 2005
    ..Open-label studies conducted in the clinic setting may provide additional drug tolerability and effectiveness information that may not be evident in pre-approval clinical trials...
  65. ncbi Three-day magnesium administration prevents atrial fibrillation after coronary artery bypass grafting
    Hiroki Kohno
    Department of Cardiovascular Surgery, Sakakibara Heart Institute, Tokyo, Japan
    Ann Thorac Surg 79:117-26. 2005
    ..The purpose of this study was to assess the effect of 3-day postoperative infusion of magnesium on postoperative atrial fibrillation and to find factors that can influence the efficacy of this treatment...
  66. ncbi The significance of prestroke aspirin dosage in fatal outcome of acute stroke
    Yair Lampl
    Department of Neurology, Edith Wolfson Medical Center, Holon, Israel
    Clin Neuropharmacol 28:55-9. 2005
    ..The association between the pretreatment aspirin dosage and fatal outcome among these treated patient groups has not been analyzed previously...
  67. ncbi Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting
    Kevin A Bybee
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Circulation 112:I286-92. 2005
    ..Aspirin is beneficial in the setting of atherosclerotic cardiovascular disease. There are limited data evaluating preoperative aspirin administration preceding coronary artery bypass grafting and associated postoperative outcomes...
  68. ncbi Long-term survival of non-elderly patients with severe heart failure treated with angiotensin-converting enzyme inhibitors assessment of treatment with captopril and enalapril survival study (ACESS)
    Chien Ming Huang
    Department of Medicine, Cheng Hsin Medical Center, Taipei, Republic of China
    Circ J 66:886-90. 2002
    ..Additional prospective large studies are necessary to verify the relationship observed here between the optimal dosage as well as the duration of action of different ACEIs and their outcomes...
  69. ncbi Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study
    Elizabeth Cittadini
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, England
    Arch Neurol 63:1537-42. 2006
    ..Cluster headache is a form of primary headache in which attacks are rapid in onset with very severe pain. The mainstays of acute therapy are inhaled oxygen and sumatriptan succinate injection...
  70. ncbi Tolerability of NXY-059 at higher target concentrations in patients with acute stroke
    K R Lees
    University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK
    Stroke 34:482-7. 2003
    ....
  71. ncbi Safety of dexamphetamine in acute ischemic stroke: a randomized, double-blind, controlled dose-escalation trial
    Louise Martinsson
    Institution of Clinical Neurosciences, Karolinska Institute, Stockholm, Sweden
    Stroke 34:475-81. 2003
    ..Limited information is available on treatment safety. This study intended to investigate the safety and tolerability of dexamphetamine in patients with acute cerebral ischemia...
  72. ncbi Phacoemulsification in patients with previous trabeculectomy: role of 5-fluorouracil
    T K Sharma
    Wolverhampton Eye Infirmary, Wolverhampton, UK
    Eye (Lond) 21:780-3. 2007
    ..This study was carried out to evaluate the protective role of subconjunctival 5-FU on the pre-existing bleb from trabeculectomy in patients undergoing phacoemulsification...
  73. ncbi Regulatory issues of importance to developing anti-HIV therapeutics
    K L Hastings
    Division of Antiviral Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland 20857, USA
    Toxicol Pathol 24:278-80. 1996
    ..HIV-related diseases are reviewed by the Division of Anti-Viral Drug Products (DAVDP) within the Center for Drug Evaluation and Research...
  74. ncbi Safety assessment programs for U.S. regulatory agencies: a perspective of requirements and compliance
    R A Bendele
    NeXagen, Inc, Boulder, Colorado 80301
    Toxicol Pathol 22:95-104. 1994
    ..the Environmental Protection Agency and for components of the Food and Drug Administration, including the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Veterinary Medicine.
  75. ncbi The effects of streptozotocin-induced hypoinsulinemia on serum lipid levels in spontaneously hyperlipidemic rats
    H Nakura
    Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan
    Horm Metab Res 29:454-7. 1997
    ..The STZ-treated HLR showed the extremely hyperlipidemic state and this animal might be useful in experiments for the development of atherosclerosis or the drug evaluation for the agents used in hyperlipidemia.
  76. ncbi The efficiency of anti-activated factor X and anti-activated factor II anticoagulants
    Thomas W Stief
    Department of Clinical Chemistry, University Hospital Giessen and Marburg, Marburg, Germany
    Blood Coagul Fibrinolysis 18:265-9. 2007
    ..e. if about 0.1 IU/ml thrombin are inactivated, then thrombin cannot self-amplify its generation 10-fold). The efficiency of any clinically used plasmatic anticoagulant can be monitored in the EXCA...
  77. ncbi Role of aldosterone blockade in heart failure
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, MI 48109 0366, USA
    Heart Fail Clin 1:49-56. 2005
  78. ncbi Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium
    Brett T Brinker
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    Cancer 112:1083-8. 2008
    ....
  79. ncbi Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder
    Stuart A Montgomery
    Imperial College School of Medicine, London, UK
    Int J Neuropsychopharmacol 9:517-28. 2006
    ..Nemifitide showed a good tolerability and safety profile. There were no dropouts due to adverse events, and the incidence of side-effects with nemifitide was comparable with that of placebo...
  80. ncbi Acaricidal and repellent properties of permethrin, its role in reducing transmission of vector-borne pathogens
    N Mencke
    Bayer HealthCare AG, Animal Health Division, Leverkusen, Germany
    Parassitologia 48:139-40. 2006
    ..To achieve this, acaricides with repellent properties, such as the synthetic pyrethroid permethrin are ideal compounds to reach this goal...
  81. ncbi Caudal epidural morphine for control of pain following open heart surgery in children
    K R Rosen
    Department of Anesthesiology, C. S. Mott Children's Hospital, Ann Arbor, Michigan 48109-0800
    Anesthesiology 70:418-21. 1989
    ..They found caudal epidural morphine to be safe and effective in the treatment of postoperative pain in children following open heart surgery...
  82. ncbi Inhaled insulin: a novel route for insulin delivery
    William T Cefalu
    University of Vermont College of Medicine, Burlington, VT, USA
    Expert Opin Investig Drugs 11:687-91. 2002
    ..The pharmacokinetics of inhaled insulin show a more physiological profile compared to conventional insulin; however, further studies to confirm long-term pulmonary safety and efficacy are needed...
  83. ncbi [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)]
    M Fukuoka
    Osaka Prefectural Habikino Hospital
    Gan To Kagaku Ryoho 17:2213-9. 1990
    ..3 to 4.1 ng/ml, and from 1.5 to 11.9 ng/ml respectively, and sustained almost the same concentration as to during the administration period until the 2nd day after the completion of the administration...
  84. ncbi Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Nadia Iovieno
    Center for Treatment Resistant Depression, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 73:676-83. 2012
    ....
  85. ncbi [Prevention of infectious complications after cesarean section by the use of cefotetan]
    P Cormier
    Service d obstétrique et de gynécologie, Maternité A, Hopital Pellegrin, Bordeaux
    J Gynecol Obstet Biol Reprod (Paris) 18:388-92. 1989
    ..It caused a significant drop in infection and in particular the number of cases of endometritis and urinary tract infections, which were twice as common in the non-treated as compared with the treated group...
  86. ncbi Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma
    Y Tamada
    Department of Ophthalmology, Gifu University School of Medicine, Gifu-shi, Japan
    J Ocul Pharmacol Ther 17:19-25. 2001
    ..The IOP level before latanoprost therapy is a contributing factor in the IOP-lowering efficacy of latanoprost. Latanoprost is more effective in lowering IOP than isopropyl unoprostone...
  87. ncbi Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes
    Alberto Grossi
    Haematologica 87:322-3. 2002
    ..5 x 10(9)/L. Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages...
  88. ncbi [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation]
    A Martinez Castelao
    Servicio de Nefrologia, Unitat Reçerca Experimental, Hospital Principes de Espana, CSUB
    Nefrologia 22:364-9. 2002
    ..Oxidation of low-density lipoprotein (LDL) has been recognized as a major atherogenic factor. Tacrolimus seems to be less lipogenic with an apparently better cardiovascular profile than CsA...
  89. ncbi Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of Clavubactin and Synulox in healthy cats
    Tom B Vree
    Institute for Anaesthesiology, University Medical Center Sint Radboud, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    ScientificWorldJournal 2:1369-78. 2002
    ....
  90. ncbi Clinical efficacy of intravenous ciprofloxacin in patients with biliary tract infection: a randomized controlled trial with carbapenem as comparator
    Susumu Tazuma
    Department of General Medicine, Hiroshima University Graduate School of Medical Science, Programs of Applied Medicine, Clinical Pharmacotherapy, 1 2 3 Kasumi, Minami Ku, Hiroshima, 734 8551, Japan
    J Gastroenterol 44:781-92. 2009
    ....
  91. ncbi Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine
    Thomas N Kakuda
    Tibotec Inc, Titusville, NJ, USA
    Antivir Ther 15:817-29. 2010
    ..In conclusion, etravirine can be combined with most antiretrovirals, with no clinically meaningful effect on drug exposure or safety/tolerability profiles...
  92. ncbi Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients
    C M Samson
    Ocular Immunology and Uveitis Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02116, USA
    Ophthalmology 108:1134-9. 2001
    ..It is an effective steroid-sparing immunomodulator, is a safe medication, and is well tolerated...
  93. ncbi On the estimation of the binomial probability in multistage clinical trials
    Sin Ho Jung
    Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27710, USA
    Stat Med 23:881-96. 2004
    ..We will illustrate features of the UMVUE based on two-stage phase II clinical trial design examples and present results of numerical studies on the properties of the UMVUE in comparison to the usual MLE...
  94. pmc Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor
    Caroline Solas
    Department of Pharmacokinetics, AP HM Timone, Marseille, France
    Br J Clin Pharmacol 57:436-40. 2004
    ....
  95. ncbi [Clinical efficacy of sulbactam/ampicillin in comparison with cefotiam in the treatment of elderly patients with pneumonia]
    T Ishibashi
    Department of Internal Medicine, National Ohmuta Hospital
    Jpn J Antibiot 51:746-58. 1998
    ..No statistical differences were noted in both groups. These results are consistent with SBT/ABPC as a highly effective antibiotic in the treatment of elderly patients with pneumonia...
  96. ncbi Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier
    Tae Hee Kim
    School of Agricultural Biotechnology, Seoul National University, Seoul 151 742, South Korea
    Biomaterials 25:3783-92. 2004
    ..And transfection efficiency into HepG2, which has asialoglycoprotein receptors (ASGP-R), was higher than that into HeLa without ASGP-R...
  97. ncbi Reduction of hepatocellular injury after common bile duct ligation using omega-3 fatty acids
    Sang Lee
    Department of Surgery, The Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    J Pediatr Surg 43:2010-5. 2008
    ..Omega-3 fatty acids are antiinflammatory. We proposed that omega-3 fatty acid supplementation would reduce hepatocellular damage and cell death in a model of murine common bile duct ligation...
  98. ncbi Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs
    M L Pacor
    Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy
    Clin Exp Allergy 32:397-400. 2002
    ..Adverse reactions to non-steroidal anti-inflammatory drugs (NSAID)s are frequent, and the need to identify a safe alternative drug is a common problem in clinical practice...
  99. ncbi The European paediatric initiative: 1 year of experience
    Agnes Saint-Raymond
    Scientific Advice, Paediatrics, and Orphan Drugs Sector, European Medicines Agency, London, UK
    Paediatr Drugs 11:9-10. 2009
    ..It changes dramatically the way medicines are developed for children. This regulation will increase availability of and information on pediatric medicines through high quality, ethical research...
  100. ncbi The newborn drug development initiative
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    Pediatrics 117:S1-8. 2006
    ....
  101. ncbi Low doses of vanadate and Trigonella synergistically regulate Na+/K + -ATPase activity and GLUT4 translocation in alloxan-diabetic rats
    Mohammad Rizwan Siddiqui
    Hormone and Drug Research Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India
    Mol Cell Biochem 285:17-27. 2006
    ..Combined therapy of vanadate and TSP was the most effective in normalization of altered membrane linked functions and GLUT4 distribution without any harmful side effect...

Research Grants83

  1. ACYLCOA FORMATION--COVALENT BINDING, PHARMACOKINETICS
    Leslie Benet; Fiscal Year: 2002
    ....
  2. INFLAMMATION & CORTICOSTEROID RESPONSES IN SEVERE ASTHMA
    KIAN CHUNG; Fiscal Year: 2005
    ..The molecular mechanisms underlying loss of CR will be examined. These studies should lead to more effective therapies for chronic severe asthma. ..
  3. Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device
    Leslie Benet; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  4. Phase I Clinical Trials of Anti-Cancer Agents
    Francis Giles; Fiscal Year: 2007
    ..abstract_text> ..
  5. Central Adaptations to Creatine Supplementation in Older Men and Women
    ERIC RAWSON; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  6. Pharmacokinetic / Pharmacodynamic Data Analysis
    Davide Verotta; Fiscal Year: 2010
    ..abstract_text> ..
  7. Role of Inter-alpha Inhibitors in Anthrax Intoxication
    Steven Opal; Fiscal Year: 2007
    ..Our research is focused on the development of a new and safe treatment based on the ability of inter-alpha proteins to prevent the fatal consequences of anthrax infection. [unreadable] [unreadable] [unreadable] [unreadable]..
  8. ANTIAIDS AGENTS FROM MARINE ORGANISMS
    Mark Hamann; Fiscal Year: 2007
    ....
  9. Immunity in Early Syphillis: Pathway to HIV Coinfection
    Juan Salazar; Fiscal Year: 2007
    ..In Aim 2 we will study the effect of secondary syphilis on viral load (VL) in HIV co-infected individuals. In this aim we will compare VL between HIV patients with and without syphilis and determine the effect of penicillin on VL. ..
  10. Phase I trial of PHP with high-dose IL-2
    Wolfram Samlowski; Fiscal Year: 2006
    ..abstract_text> ..
  11. Chamomile therapy for generalized anxiety disorder
    Jay Amsterdam; Fiscal Year: 2006
    ....
  12. A Family-Genetic Study of Pathological Gambling
    Donald Black; Fiscal Year: 2009
    ..abstract_text> ..
  13. AFP-Based Immunotherapy for Hepatocellular Carcinoma
    Antoni Ribas; Fiscal Year: 2006
    ..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..
  14. Black cohosh therapy for menopause-related anxiety
    Jay Amsterdam; Fiscal Year: 2006
    ..We hypothesize that Black Cohosh will result in superior QOL measures compared to placebo. ..
  15. CARP, A Novel Cell Death Regulator
    Wafik El Deiry; Fiscal Year: 2006
    ..Specific Aim 3: To study the functional consequences of perturbing or blocking CARP expression. These studies should provide novel insights into the cellular control of the extrinsic pathway of apoptosis. ..
  16. Genetic Vaccine to Rabies Virus
    Hildegund Ertl; Fiscal Year: 2006
    ..In aim 3, we are proposing experiments in non-human primates to test the vaccine for efficacy in pre- and post-challenge vaccination experiments with and without concomitant application of RIG. [unreadable] [unreadable]..
  17. Unique BRCA1 transcriptional response leading to repair
    Wafik El Deiry; Fiscal Year: 2006
    ..Our studies will increase our understanding of the mechanism of action of BRCA1 and may provide novel strategies for therapeutic design, for example by targeting DDB2. ..
  18. Influences on Sexual Health
    MARGAERT NUSBAUM; Fiscal Year: 2007
    ..Nusbaum with experience crucial to her growth as an independent academic researcher in sexual health care. ..
  19. NEUROBIOLOGY OF TRANSITION TO STIMULANT DEPENDENCE
    Martin P Paulus; Fiscal Year: 2010
    ..g. using real-time fMRI?? ..
  20. Heart failure, chronic kidney disease, and renin-angiotensin system inhibition
    Ali Ahmed; Fiscal Year: 2009
    ....
  21. Fluoxetine for MDD/Cannabis Disorder in Young People
    Jack Cornelius; Fiscal Year: 2009
    ..abstract_text> ..
  22. EARLY VISUAL PROCESSING IN SCHIZOPHRENIA
    Michael F Green; Fiscal Year: 2010
    ....
  23. TOBACCO EXPOSURE REDUCTION
    Dorothy Hatsukami; Fiscal Year: 2008
    ..The results of research from this TTURC will provide the scientific basis for urgent policy, public education, and regulatory efforts to reduce tobacco harm. ..
  24. Procoagulants in Aging CARDIA Participants
    David Green; Fiscal Year: 2009
    ....
  25. TREATMENT OF SMOKELESS TOBACCO USERS
    Dorothy Hatsukami; Fiscal Year: 2008
    ..PERFORMANCE SITE ========================================Section End=========================================== ..
  26. Tamsulosin and steroids for urolithiasis
    Jeremy Brown; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  27. Respiratory Viruses and Airflow Obstruction after HCT
    Michael Boeckh; Fiscal Year: 2008
    ..These studies will improve our understanding of the interaction between respiratory viruses and late pulmonary complications after HCT, which will ultimately enable us to formulate more rational treatment strategies. ..
  28. Time processing in stimulant users: Impulsivity and temporal discounting
    Martin Paulus; Fiscal Year: 2008
    ..The current study will inform treatment programs to create intervention strategies that manipulate the temporal delay of rewards to shape more adaptive behavior. [unreadable] [unreadable] [unreadable]..
  29. REVAMP Follow-Up Study
    Martin Keller; Fiscal Year: 2008
    ....
  30. Abuse Liability Associated with Chronic Hypnotic Use
    Timothy Roehrs; Fiscal Year: 2008
    ....
  31. TUMOR RADIOSENSITIZATION BY PRENYLTRANSFERASE INHIBITORS
    Eric Bernhard; Fiscal Year: 2008
    ..They may also provide a rationale for the application of FTIs in the treatment of tumors with RAS activation that is due to EGFR signaling. [unreadable] [unreadable]..
  32. Course of psychopathology in female youth: Analysis with extant longitudinal data
    Joseph Biederman; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  33. Heart Failure and Beta-Blocker Use in Older Adults
    Ali Ahmed; Fiscal Year: 2006
    ..abstract_text> ..
  34. WEIGHT CONTROL IN PERI- AND EARLY POSTMENOPAUSAL WOMEN
    SUSAN RACETTE; Fiscal Year: 2001
    ..The results of this project are intended to provide valuable information regarding lifestyle programs that may assist women in controlling body weight at a time when weight gain is common. ..
  35. CLINICAL TRANSLATIONAL RESEARCH IN DERMATOLOGY
    Sewon Kang; Fiscal Year: 2004
    ..abstract_text> ..
  36. E1-deleted adenoviral vectors for oral immunization
    Hildegund Ertl; Fiscal Year: 2004
    ..In aim 4, we will determine the tropism of the simian and human Ad recombinants upon oral application emphasizing localization of and cytokine production by transduced antigen presenting cells (APCs). ..
  37. EXERCISE INTOLERANCE IN ELDERLY DIASTOLIC HEART FAILURE
    Dalane Kitzman; Fiscal Year: 2004
    ..abstract_text> ..
  38. OLFACTION IN EPILEPSY
    RICHARD DOTY; Fiscal Year: 2004
    ..In addition to providing a better understanding of the influences of TLE and TLR on human olfactory function, this work may lead to the development of a simple and inexpensive non-invasive means for better establishing TLE seizure loci. ..
  39. PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME
    JAMES LEEDER; Fiscal Year: 2003
    ..It is anticipated that the basic experimental paradigm employed for these studies can also be applied to other idiosyncratic toxicities with suspected drug bioactivation and immune etiologies. ..
  40. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  41. CBL FUNCTION IN CELLULAR SIGNALING AND TRANSFORMATION
    Brian Druker; Fiscal Year: 2003
    ..Through these studies the investigators should gain a greater understanding of the contribution of tyrosine phosphorylation of Cbl to its function and the role of Cbl in myeloid transformation. ..
  42. APPROACHES TO CHARACTERIZATION OF ANTIINFECTIVE AGENTS
    Mark Hamann; Fiscal Year: 2002
    ..SAR studies will be conducted utilizing chemical and microbial transformations of biologically active secondary metabolites combined with molecular modeling studies. ..
  43. FFA METABOLISM IN DIFFERENT TYPES OF HUMAN OBESITY
    Michael Jensen; Fiscal Year: 2002
    ....
  44. Mucosal Vaccine to HIV-1 Gag
    Hildegund Ertl; Fiscal Year: 2002
    ..In the third aim, we will test a prime-boost regimen using DNA vaccines, expressing Gag for systemic priming combined with the adenoviral recombinants for systemic or intranasal booster immunization. ..
  45. COST EFFECTIVENESS OF GENETIC SCREENING FOR COLON CANCER
    Scott Ramsey; Fiscal Year: 2002
    ....
  46. HIV-1 Vaccine-Induced CD8+ Memory Cells
    Hildegund Ertl; Fiscal Year: 2003
    ..The role of the two different memory CD8+ T cell populations in limiting propagation of the vaccinia gag recombinant virus will be tested by adoptive transfer experiments. ..
  47. IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERS
    Kelly Gebo; Fiscal Year: 2005
    ..Gebo the skills she needs to develop into an independent clinician researcher in HIV epidemiologic and health services research. ..
  48. Prednisone Ocular Myasthenia Gravis Trial Planning Grant
    Mark Kupersmith; Fiscal Year: 2004
    ....
  49. DEPRESSION AND HEALTH OUTCOMES IN REFRACTORY EPILEPSY
    Frank Gilliam; Fiscal Year: 2005
    ..of the results of a positive study will support the modification of the current model of intervention for epilepsy from predominantly seizure reduction to a more comprehensive approach that includes assessment and treatment of depression ..
  50. Mentored Patient Oriented Research Career Development
    Diana Escolar; Fiscal Year: 2005
    ..Future studies will test several other drugs with potential to improve muscle strength in DMD. ..
  51. Pulmonary delivery of nicotine using the AERx System
    Stephen Farr; Fiscal Year: 2005
    ..The long-term goal of this proposed project is to develop an inhalation product (the AERx-nicotine) as a therapy for smoking cessation. ..
  52. A Contextual Model of Microbicide Acceptability
    Kathleen Morrow; Fiscal Year: 2005
    ..abstract_text> ..
  53. Oxidative Modifications in Atherogenesis
    Garret FitzGerald; Fiscal Year: 2006
    ..abstract_text> ..
  54. A Cognitive Group Treatment for Borderline Outpatients
    Donald Black; Fiscal Year: 2005
    ..abstract_text> ..
  55. MDMA & Amphetamine--Behavioral Organization in Mice
    Martin Paulus; Fiscal Year: 2003
    ..The results from these studies will provide a set of measures derived from a widely used behavioral paradigm to examine the molecular basis of the effects of drugs of abuse using genetically modified mice. ..
  56. Improving Outcomes in Pharmacotherapy of Social Phobia
    Michael Van Ameringen; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  57. Female Condom Use in South African College Students
    Joanne Mantell; Fiscal Year: 2008
    ..If successful, this brief intervention should be widely replicable in other similar settings. ..
  58. Critical Research Issues in Essential Tremor
    Rodger Elble; Fiscal Year: 2005
    ..We believe that such conferences are the best way to build and maintain momentum and interest in ET research. ..
  59. RETINAL PATHOPHYSIOLOGY OF INFANTS AND ADULTS
    David Birch; Fiscal Year: 2005
    ..In the mouse models, cone measures will necessarily focus on the b-wave, using monochromatic stimuli, long-duration flashes, and flicker to optimize isolation of cone from rod responses. ..
  60. Estrogen-Induced Neuroprotective Mitochondrial Mechanism
    ROBERTA BRINTON; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  61. COMBINATORIAL PHARMACOTHERAPIES FOR COCAINE DEPENDENCE
    John Cashman; Fiscal Year: 2001
    ..The study will provide an understanding of the structural and pharmaceutical properties of hDAT antagonists. The work will lead to new insight into the preparation of human medications necessary in the cessation of cocaine abuse. ..
  62. NF KAPPA B MEDIATED CHEMORESISTANCE IN HUMAN LUNG CANCER
    David Jones; Fiscal Year: 2005
    ..The ultimate goal of this study is to provide the necessary background for the initiation of novel treatment strategies designed to treat patients with advanced lung cancer. ..
  63. Disclosing Conflict of Interest to Research Participants
    Jeremy Sugarman; Fiscal Year: 2008
    ..abstract_text> ..
  64. STRAIT: Simulation Training for Rapid Assessment and Improved Teamwork
    Matthew Weinger; Fiscal Year: 2007
    ..Successful demonstration of STRAIT'S effectiveness will lead to rapid dissemination of the methods to other clinical handoff situations. [unreadable] [unreadable] [unreadable]..
  65. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
    ..This K23 grant application will serve as a springboard to allow her to delve into the pathophysiology of this syndrome and to develop into an independent clinical investigator. ..
  66. Community Partnership for Ethical Research
    ELIZABETH B RIPLEY; Fiscal Year: 2010
    ....
  67. Unexpected Clinical Events: Impact on Patient Safety
    Matthew Weinger; Fiscal Year: 2003
    ..The proposed studies, while yielding applied knowledge of specific ways to reduce medical error and improve clinical care, also address more fundamental issues of human cognition and the nature of expertise. ..
  68. Sustained-Release Naltrexone for Opioid Dependence: Longitudinal Study in Humans
    Sandra D Comer; Fiscal Year: 2010
    ....
  69. BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
    Stephen Ansell; Fiscal Year: 2008
    ..abstract_text> ..
  70. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
    ..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
  71. BUPRENORPHINE ABUSE BY HUMANS--LABORATORY STUDIES
    Sandra Comer; Fiscal Year: 2002
    ....
  72. Bupropion VS Placebo to Treat Pathological Gambling
    Donald Black; Fiscal Year: 2004
    ..abstract_text> ..
  73. GERIATRIC CLINICAL EPIDEMIOLOGY TRAINING GRANT
    STEVEN HALBERT; Fiscal Year: 2007
    ..g., clinical trials, case control, cohort research, etc.), and the faculties' commitment to collaborative research. [unreadable] [unreadable]..
  74. Oregon Prostate Cancer Conference 2001
    TOMASZ BEER; Fiscal Year: 2003
    ....
  75. Heart Failure: Epidemiology & Outcomes in the Elderly
    Lesley Curtis; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  76. Pramipexole in Treatment-Resistant Depression
    Roy Perlis; Fiscal Year: 2007
    ..The proposed investigation and training program will provide critical skills, experience and data to aid the candidate in writing an R01 and becoming an independent investigator. ..
  77. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
    ..obtain longitudinal toxicity and quality of life data on this same cohort of 50 patients and will make direct comparisons between treatment arms on toxicity incidence and severity and on maximal quality of life scores ..
  78. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2009
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
  79. SPECT Brain Imaging as a Biomarker of Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..We will compare these results to measurements of striatal DAT levels in 22 non-depressed, healthy subjects studied under similar conditions with [99mTc]TRODAT-1 SPECT on two separate occasions 8 weeks apart. ..
  80. A Novel Vitamin D Target in Human Prostate Cancer
    TOMASZ BEER; Fiscal Year: 2007
    ..New treatment targets are needed to develop new drugs to treat prostate cancer, the most commonly diagnosed cancer and the second-leading cancer killer in US men. [unreadable] [unreadable]..